Cognition Therapeutics Inc. has announced the publication of Phase 2 clinical results for zervimesine (CT1812) in participants with mild-to-moderate dementia with Lewy bodies $(DLB)$. The data, published in the journal Alzheimer's & Dementia, demonstrated that zervimesine led to improvements in behavioral, functional, cognitive, and movement measures compared to placebo. The Phase 2 SHIMMER study met its primary endpoint of confirming the safety and tolerability of zervimesine, and showed favorable effects on several core clinical features of DLB, including cognitive fluctuations and activities of daily living. Results from the study were first presented in January 2025 at the International Lewy Body Dementia Conference. The U.S. Food and Drug Administration is scheduled to meet with Cognition Therapeutics in the second half of January 2026 to discuss the next clinical studies for zervimesine in DLB.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cognition Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620333-en) on January 06, 2026, and is solely responsible for the information contained therein.